Cybin, Inc. (TSE:CYBN) has released an update.
Cybin Inc., a biopharmaceutical company, has announced positive feedback from the FDA regarding the Phase 2 study of their deuterated psilocybin analog, CYB003, aimed at treating Major Depressive Disorder. The company is set to initiate a Phase 3 study in mid-2024, targeting 15 U.S. sites, with plans to expand into Europe. The trial follows promising results showing a significant remission rate in depression symptoms, bolstered by the FDA’s Breakthrough Therapy Designation, which could expedite the review process.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
